NCT05521087 2025-06-22
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
Janssen Research & Development, LLC
Phase 1 Withdrawn
Janssen Research & Development, LLC
Amgen
Chongqing Peg-Bio Biopharm Co., Ltd.
Enzon Pharmaceuticals, Inc.